ImmunityBio, Inc. - Common Stock (IBRX)

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

NEW ORLEANS, April 02, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). ImmunityBio investors have until May 26, 2026 to file a lead plaintiff motion.

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (ImmunityBio) (NASDAQ: IBRX) on behalf of those who purchased or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, inclusive. The lawsuit is filed in the United States District Court for the Central District of California and is captioned Douglas v. ImmunityBio, Inc., Case No. 2:26-cv-03261 (C.D. Cal.). Investors have until May 26, 2026, to file for lead plaintiff status.

NEW YORK CITY and NEW ORLEANS, March 31, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

Institutional investors holding positions in ImmunityBio, Inc. (NASDAQ: IBRX) during the period January 19, 2026 through March 24, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Shares lost $1.98 per share, a 21% decline, after an FDA Warning Letter exposed allegedly false promotional claims about the Company's lead drug, ANKTIVA. Request an institutional investor loss assessment or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). ImmunityBio investors have until May 26, 2026 to file a lead plaintiff motion.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). ImmunityBio investors have until May 26, 2026 to file a lead plaintiff motion.

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) between January 19, 2026, and March 24, 2026, inclusive. What To Do Next:

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced it has secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital, increasing the total committed capital under the Agreement to $375 million. The amended agreement maintains existing terms, with a modest increase in the royalty payback rate while maintaining the royalty cap.

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ImmunityBio (IBRX) To Contact Him Directly To Discuss Their Options

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of federal securities laws.

The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, both dates inclusive (the “Class Period”), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v. ImmunityBio, Inc., No. 26-cv-03261 (C.D. Cal.), the ImmunityBio class action lawsuit charges ImmunityBio and ImmunityBio’s Executive Chairman with violations of the Securities Exchange Act of 1934.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”).

The Law Offices of Frank R. Cruz announces an investigation of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ImmunityBio investors under the federal securities laws.

A diverse group of small- and mid-cap companies across defense technology, digital assets, biotech, energy, and education are drawing increased investor focus as new developments signal potential momentum heading into the next market cycle. From U.S. Marine Corps VR deployments to $1B debt reduction moves and biotech trial validation, multiple sectors are driving renewed investor attention.